Stock Mumak

Stock Profile

Moderna

Moderna strengthens its mRNA platform with positive Phase 3 data in oncology and the approval of MFLUSIVA; however, financial risks remain high.
Moderna
Pharmaceuticals & Biotechnology

Valuation Analysis: Moderna

ISIN: US60770K1079

Moderna is undergoing a transition from a COVID-19 vaccine provider to a broader mRNA biotechnology platform. Positive Phase 3 data for autogene intismeran in melanoma and the FDA approval of MFLUSIVA strengthen the outlook in oncology and respiratory diseases. At the same time, high losses, cash burn, and regulatory risks continue to weigh on the overall outlook.

Latest Portfolio Updates

Weekly Update

Weekly Market Overview – October 19–October 25, 2026

Lockheed Martin newly added to the portfolio, Intel sold completely, and the technology sector under pressure: The UMBRELLA Strategy continues
Next Update
Weekly Update

Weekly Market Overview – October 12–October 18, 2026

Defense back in focus, Alphabet gains significance, and the healthcare sector takes the lead: The UMBRELLA Strategy realigns its portfolio
Next Update
Strategy in Action

Alphabet – Position Further Increased

The UMBRELLA strategy further increases its Alphabet position. The focus is on the growth potential of artificial intelligence, Google Cloud,
Next Update
Weekly Update

Weekly Market Overview – October 5–October 11, 2026

Palantir becomes the largest UMBRELLA position. SpaceX gains, Dell is added, and Bayer exits. The focus on AI and technology
Next Update
All Portfolio Updates